AUSTRALIAN DRUG DEVELOPMENT BLOG
The Latest Blogs from Agilex Biolabs

Author By Agilex BiolabsPosted on
Introduction – A New Chapter in Drug Development The use of biomarkers in medicine is not new. Long before the rise of modern...

Author By Agilex BiolabsPosted on
By Dr Hayley Kain, Pharmacokinetic Scientist at Agilex Biolabs Rapid Data. Smarter Decisions. No Delays. In early-phase clin...

Author By Agilex BiolabsPosted on
By Dr. Kurt Sales, CSO Section Summary: How Agilex has emerged as a leader to support the rise of natural products, includi...

Author By Agilex BiolabsPosted on
By Dr. Kurt Sales, CSO Summary The following article focuses on the use of flow cytometry in clinical trials and the use of...

Author By Agilex BiolabsPosted on
By William Grenfell, Head of IT In today's digital age, information security is paramount. At Agilex Biolabs, we understand the...

Author By Agilex BiolabsPosted on
By Kim Salvatore, Head of Client and Operational Services The bioanalytical and drug development industry is at the forefront o...

Author By Agilex BiolabsPosted on
There’s a great opportunity for Australian SME’s to take advantage of a well-deserved subsidy! Agilex Biolabs is thrilled t...

Author By Agilex BiolabsPosted on
Research shows that Biotechnology companies have been facing significant challenges – with continual declines in deal making act...

Author By Agilex BiolabsPosted on
By Dr. Kurt Sales, CSO Introduction Immunological assays are essential in drug development, especially for immunomodulatory...

Author By Agilex BiolabsPosted on
By Dr. Kurt Sales, CSO Peripheral Blood Mononuclear Cells (PBMC) are critical for the pharmacodynamic assessment of new drug pr...

Author By Agilex BiolabsPosted on
The Role of Peripheral Blood Mononuclear Cells (PBMCs) in Drug Discovery and Clinical Trials. By Dr. Kurt Sales, CSO In the...

Author By Agilex BiolabsPosted on
Oligonucleotide Analysis By Dr. Kurt Sales, CSO Oligonucleotides, including small interfering RNA (siRNA) and antisense olig...